Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18824273 | 1.00 | CACNA1H (0.47) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL376112 | 0.91 | CACNA1H (0.47) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL31301242 | 0.79 | DRD2 (0.63) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL6007685 | 0.76 | SLC6A1 (0.46) | CACNA1HDRD2MEN1KMT2AEPHX1 | |
| SCHEMBL6007677 | 0.76 | SLC6A1 (0.46) | CACNA1HDRD2MEN1KMT2AEPHX1 | |
| SCHEMBL376066 | 0.75 | DRD2 (0.42) | CACNA1HDRD2ALDH1A1GFERJAK2 | |
| SCHEMBL13202614 | 0.75 | DRD2 (0.59) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL21273876 | 0.75 | EPHX1 (0.43) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL24811481 | 0.75 | CACNA1H (0.52) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL18233672 | 0.75 | CACNA1H (0.49) | CACNA1HDRD2MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2018-11-01 | — | — | US | disclosed |
| WO-2017075694-A1 | ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR | SIMON FRASER UNIVERSITY (CA) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | UGT1A8, CYP2C8, CXCL8 | CACNA1H 4003/4885DRD2 4251/4885MEN1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.